Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elaine K. Sorg received a stock option grant for 16,250 shares of common stock on September 10, 2026. The option has an exercise price of $10.42 per share, expires on September 9, 2036, and will vest in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting. After this grant, she holds options for 16,250 shares directly, and no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Elizabeth L. Hougen received a grant of 16,250 director stock options on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036. The award vests in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting, and no Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Brian Daniels received a grant of stock options for 16,250 shares of common stock on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036.
The options vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting. After this grant, Daniels holds stock options covering 16,250 shares directly. No Rule 10b5-1 trading plan is reported for this award.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option grant on September 10, 2026 covering 16,250 shares of common stock at an exercise price of $10.42 per share. The option vests in full on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting and expires on September 9, 2036.
Artiva Biotherapeutics, Inc. (ARTV) reported that director Alison Moore received a grant of options to purchase 16,250 shares of common stock on September 10, 2026. The options have an exercise price of $10.42 per share and will vest in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting, and expire on September 9, 2036. No Rule 10b5-1 trading plan is reported for this award.
Artiva Biotherapeutics, Inc. (ARTV) reported that President & Head of R&D Diego Miralles Gines received equity awards on September 9, 2026. He was granted options to purchase 135,000 shares of common stock at an exercise price of $10.79 per share, expiring September 8, 2036, and a separate grant of 45,000 restricted stock units under the 2024 Equity Incentive Plan. After these grants, he directly holds 122,500 shares of common stock and 135,000 option shares. No Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Tech Operations Officer Christopher Horan received equity awards on September 9, 2026. He was granted 40,000 shares of Common Stock as a restricted stock unit award under the 2024 Equity Incentive Plan and options for 120,000 shares of Common Stock at an exercise price of $10.79 per share, expiring September 8, 2036. Following these awards, he directly holds 323,084 Common Shares and 120,000 stock options. The option award vests in equal monthly installments over four years, beginning September 8, 2026, and no Rule 10b5-1 trading plan is indicated.
Artiva Biotherapeutics, Inc. (ARTV) reported that officer Jennifer Bush, who serves as COO, CLO and Compliance Officer, received equity awards on September 9, 2026. She was granted options to buy 135,000 shares of common stock at an exercise price of $10.79 per share, expiring September 8, 2036, and a 45,000-share restricted stock unit award. Following these awards, she directly holds 374,529 shares of common stock, and the option begins vesting in equal monthly installments from September 8, 2026 over four years. No Rule 10b5-1 plan is reported for these awards.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee received equity compensation on September 9, 2026. He was granted 30,000 shares of common stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan and now directly holds 170,947 common shares.
He was also granted 85,000 stock options to purchase common stock at an exercise price of $10.79 per share, expiring on September 8, 2036. Beginning on September 8, 2026, one forty-eighth of the option shares vests in equal monthly installments over four years. No Rule 10b5-1 trading plan is reported.
Artiva Biotherapeutics, Inc. (ARTV) reported the results of its 2026 Annual Meeting of Stockholders held on September 8, 2026. Stockholders approved an amendment to the company’s 2024 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance under the plan by 5,097,095 shares and to include shares issuable upon exercise of pre-funded warrants in the plan’s annual automatic share reserve increase calculation.
Stockholders also elected Class II directors Brian Daniels, M.D., and Laura Stoppel, Ph.D., each to serve a three-year term through the 2029 annual meeting, and ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. There were 48,885,777 shares of common stock outstanding and entitled to vote as of the July 20, 2026 record date.